The World Health Organization said eradicating malaria is biologically feasible and a lofty aim, but the focus for now should be getting the funds, tools and political will to control the mosquito-borne disease.
An unnamed Novartis executive sold 925,400 Swiss francs ($946,000) worth of shares less than three weeks before the U.S. Food and Drug Administration announced data from tests of the company’s gene therapy Zolgensma had been manipulated.
The only liver disease becoming more widespread in the U.S. is one driven by obesity and diabetes – NAFLD – even as other liver disorder types linked to drinking or hepatitis become less common.
Novartis named company veteran Victor Bulto as head of the Swiss drugmaker’s U.S. pharmaceuticals business, effective Sept. 1, 2019.
The U.S. government’s deficit widened to $120 billion in July 2019, fueled by increases in spending on health care and the military, according to data released by the Treasury Department.
Days after the U.S. FDA revealed data manipulation was involved in the early studies of Novartis’ multi-million dollar gene therapy for SMA, U.S. Senate members demanded the regulatory agency take action against AveXis, the company that developed Zolgensma.
During the year following the launch of a new product, a good commercial operations team should accumulate an abundance of helpful sales-related data. Analyzed properly, that data can help executives make better decisions and improve the product’s chances for long-term success. The challenge is: Where to start? How can the commercial team use sales data to better target physicians and better direct the sales force?
Roche Holding’s Tecentriq drug combined with platinum-based chemotherapy reduced the risk of the disease worsening or death in patients with advanced bladder cancer.
The U.S. Food and Drug Administration approved the anti-PD-1 therapy Keytruda as a monotherapy for patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 with disease progression after one or more previous lines of systemic therapy.
Intra-Cellular Therapies shares fell after the company announced that the FDA canceled the advisory committee meeting to discuss the New Drug Application for the schizophrenia drug lumateperone.